Literature DB >> 1401948

The development of enzyme-linked immunosorbent assays (ELISA) for the catecholamines adrenalin and noradrenalin.

J F Murphy1, D H Davies, C J Smith.   

Abstract

Monoclonal antibodies have been raised against adrenalin and noradrenalin and used as the basis of enzyme-linked immunosorbent assays (ELISA) to detect and estimate the concentrations of these catecholamines. Inhibition assays are described, with sensitive quantification in the range from 1 mg/ml to 100 pg/ml. Cross-reactivity assays reveal that neither assay is subject to interference by catecholamine metabolites at concentrations less than 100 ng/ml and 1 micrograms/ml respectively. Isolation and quantification of both catecholamines from clinical samples is discussed and the potential application of these ELISAs in a clinical setting is proposed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401948     DOI: 10.1016/0022-1759(92)90216-g

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Protective effect of Melothria maderaspatana leaf fraction on electrolytes, catecholamines, endothelial nitric oxide synthase and endothelin-1 peptide in uninephrectomized deoxycorticosterone acetate-salt hypertensive rats.

Authors:  Chinnadurai Veeramani; Khalid S Al-Numair; Govindasamy Chandramohan; Mohammed A Alsaif; Kodukkur Viswanathan Pugalendi
Journal:  J Nat Med       Date:  2012-01-14       Impact factor: 2.343

2.  A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites.

Authors:  Li Xie; Liqin Chen; Pan Gu; Lanlan Wei; Xuejun Kang
Journal:  J Vis Exp       Date:  2018-03-01       Impact factor: 1.355

3.  A potential benefit of albinism in Astyanax cavefish: downregulation of the oca2 gene increases tyrosine and catecholamine levels as an alternative to melanin synthesis.

Authors:  Helena Bilandžija; Li Ma; Amy Parkhurst; William R Jeffery
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.